title: Regorafenib in the Real-Life Clinical Practice: Data from the Czech Registry.
abstract: To describe the use of regorafenib for the treatment of metastatic colorectal cancer (mCRC) in clinical practice in the Czech Republic, and to describe the clinical outcomes of patients in terms of safety and survival.
  
  
  
  The data of patients treated with regorafenib were extracted from the national CORECT registry. The CORECT registry is a non-interventional post-marketing database, gathering information about patients with CRC and treated with targeted agents. Twenty oncology centres in the Czech Republic contributed to this registry. Collected data included patients' characteristics, disease history, cancer treatments, response to treatments and safety.
  
  
  
  A total of 148 patients treated with regorafenib in clinical practice were analysed. At regorafenib initiation, almost all patients were fully active or slightly restricted in physical activity. Regorafenib was not administered as first-line treatment in any patient. Median progression-free survival was 3.5 months and median overall survival was 9.3 months. One-year survival rate was 44.6 %. Four partial responses were observed and 51 stable diseases. Progression was observed in 66 patients (44.6 %). The main reported adverse events were skin toxicity (5.4 %) and fatigue (2.0 %).
  
  
  
  Regorafenib is a well-established treatment for pretreated patients with mCRC, however real-life data are scarce. Our results demonstrated slightly better efficacy of regorafenib and better safety profile in patients with mCRC compared to the randomised trials.
authors.affiliation: Department of Oncology, University Hospital in Motol, Charles University, V Uvalu 84, 150 00, Prague, Czech Republic. Katerina.Kopeckova@fnmotol.cz.
authors.forename: Katerina
authors.initials: K
authors.lastname: Kopeckova
authors.affiliation: Department of Oncology, First Faculty of Medicine and Thomayer Hospital, Charles University, Prague, Czech Republic.
authors.forename: Tomas
authors.initials: T
authors.lastname: Buchler
authors.affiliation: Institute of Biostatistics and Analysis, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
authors.forename: Zbynek
authors.initials: Z
authors.lastname: Bortlicek
authors.affiliation: Institute of Biostatistics and Analysis, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
authors.forename: Karel
authors.initials: K
authors.lastname: Hejduk
authors.affiliation: Institute of Biostatistics and Analysis, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
authors.forename: Renata
authors.initials: R
authors.lastname: Chloupkova
authors.affiliation: Department of Oncology, Palacky University Medical and Teaching Hospital, Olomouc, Czech Republic.
authors.forename: Bohuslav
authors.initials: B
authors.lastname: Melichar
authors.affiliation: Department of Oncology, University Hospital in Motol, Charles University, V Uvalu 84, 150 00, Prague, Czech Republic.
authors.forename: Petra
authors.initials: P
authors.lastname: Pokorna
authors.affiliation: Department of Oncology, Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
authors.forename: Jiri
authors.initials: J
authors.lastname: Tomasek
authors.affiliation: Department of Oncology, University Hospital in Motol, Charles University, V Uvalu 84, 150 00, Prague, Czech Republic.
authors.forename: Zdenek
authors.initials: Z
authors.lastname: Linke
authors.affiliation: Department of Oncology, General Faculty Hospital, Charles University, Prague, Czech Republic.
authors.forename: Lubos
authors.initials: L
authors.lastname: Petruzelka
authors.affiliation: Department of Oncology, General Faculty Hospital, Charles University, Prague, Czech Republic.
authors.forename: Igor
authors.initials: I
authors.lastname: Kiss
authors.affiliation: Department of Oncology, University Hospital in Motol, Charles University, V Uvalu 84, 150 00, Prague, Czech Republic.
authors.forename: Jana
authors.initials: J
authors.lastname: Prausova
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018153:Czech Republic; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D010671:Phenylurea Compounds / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D011725:Pyridines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D012042:Registries
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D011725:Pyridines; C559147:regorafenib